Other Diseases

J&J touts success of nipocalimab in two rare disease trials

Johnson & Johnson (J&J) has announced positive topline results for nipocalimab in two rare disease indications - generalised myasthenia gravis…

EASD 2023: meta-analysis shows tirzepatide superiority to semaglutide

At the 59th Annual European Association for the Study of Diabetes (EASD) 2023 meeting, a new meta-analysis has shown the…

Kashiv completes Phase I trial for Xolair biosimilar

US-based Kashiv Biosciences has successfully completed a Phase I trial for its Xolair biosimilar ADL018, the company’s latest biosimilar in…

FDA reviews protocol of NLS Pharmaceutics’ study of Mazindol ER

The US Food and Drug Administration (FDA) has reviewed the full protocol of NLS Pharmaceutics’ NLS-1031 study, which is part…

Chinook reports data from Phase I trial of CHK-336

Chinook Therapeutics has reported results from a Phase I trial evaluating CHK-336, an oral small molecule LDHA inhibitor, in development…

Mirum completes enrollment of Phase IIb trial for biliary atresia

Mirum has completed enrollment for its Phase IIb EMBARK study evaluating Livmarli (maralixibat) in infants with biliary atresia who have…

Omega-3 Fatty Acids May Reduce Risk of Chronic Kidney Disease

Chronic kidney disease (CKD) is a condition characterised by a gradual loss of kidney function over time, leading to the…

Pipeline Moves: Phase II cancer trial of Roche asset terminated, shot at further study drops

In this week’s Pipeline Moves, we start off with the termination of an investigator-led Phase II cancer study of Roche’s…

Failure for Servier and Neurochlore’s autism drug, but potential remains in market

On 7 September, Servier and Neurochlore announced that following a lack of efficacy of bumetanide for autism spectrum disorder (ASD)…

Revised Covid-19 vaccine prices likely by the fall in the US but premium pricing possibility debatable

Companies with authorised Covid-19 vaccines in the US are likely to launch renegotiated prices as soon as the fall, experts…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close